Imagine a tiny, flexible robot that can swim through the natural fluid channels of the spine to reach the deep parts of the brain. Instead of risky open surgery, this robot acts like a delivery vehicle that drops off a small, porous sponge soaked in medicine exactly where it's needed. This allows doctors to treat brain diseases without affecting healthy areas of the brain.
Current treatments for neurological disorders are often ineffective because drugs cannot reach deep-brain regions without highly invasive surgery. This leads to poor efficacy and significant side effects from systemic dosing.
A submillimeter soft-growing steerable robot and microfabricated porous scaffolds (TCPs) for localized drug/cell delivery.
If you are a drug developer dealing with compounds that cannot cross the blood-brain barrier — this project developed a robotic delivery platform and tissue construct payloads that enable optimal compound dosing at specific brain regions with minimal side effects.
If you are a device maker dealing with the limitations of current invasive brain surgery — this project developed a submillimeter soft-growing steerable robotic platform that navigates the ventricular system under real-time MRI feedback.
If you are a biotech firm dealing with the difficulty of delivering cells to deep-brain targets — this project developed microfabricated deployable porous scaffolds that can attach stably to brain ventricle walls to release cells locally.
Based on available project data, the specific unit cost or market price is not provided; however, the project received an EU contribution of EUR 2,158,000 for development.
The project is currently in the demonstration phase using high-fidelity phantoms and mice. Based on available project data, industrial scaling plans are not yet detailed.
The project involves a consortium of 5 partners including a research center and an SME. Based on available project data, specific patent filings or licensing terms are not listed.
The project period runs from 2023-02-01 to 2026-07-31. Clinical translation follows the current phase of phantom and animal testing.
The system is specifically designed to work under real-time MRI guidance, meaning it integrates with existing MRI imaging infrastructure.
The consortium consists of 5 partners across 4 countries, showing a strong academic-research lean with 3 universities and 1 research center. There is a 20% industry presence via 1 SME, suggesting the project is currently focused on high-risk technical validation rather than immediate commercial rollout.
Contact IDRYMA TECHNOLOGIAS KAI EREVNAS in Greece
Contact us to explore licensing opportunities for the soft-robotic delivery hardware.
